Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Fabien Zoulim et al.|Journal of Hepatology|2022Cited by 121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA SequencingGuang Li, Yang Li, Bowen Zhang et al.|Cellular and Molecular Gastroenterology and Hepatology|2021Cited by 35
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Gastroenterology|2023Cited by 23
LB01 SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR TREATMENT OF ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: FINAL RESULTS OF THE THE GERMAN HEPNET ACUTE HCV IV STUDYKatja Deterding, Maurizio Degiuli, Christoph D. Spinner et al.|United European Gastroenterology Journal|2016Cited by 5